drugset / Trial / NCT01048463

Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

NCT01048463 ↗

Phase 3 Unknown 90 enrolled Sun Yat-sen University
RandomizedParallel-groupDouble-blindTreatment

Summary

Malnutrition is frequently seen in patients on chemotherapy suffering from gastric/colorectal cancer and may worsen the outcome. EPA, a sort of ω-3 PUFA, can modulate immune system. EPA also antagonizes metabolic and inflammatory changes induced by the tumor. This study is to test whether EPA, in combination with enteral nutrition, can improve nutritional/immunologic status, quality of life, and reduce chemotherapy related side effects of these patients.

Timeline

Start
2009-12
Primary completion
2011-12
Completion
2012-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject EPA Unknown 3 g —
Subject EPA Unknown 6 g —
Background Capecitabine Small molecule 1000 mg/m2 —
Background Oxaliplatin Small molecule 135 mg/m2 —